Laurens Rademacher joined Gylden as Chief Technology Officer in January 2016. He is responsible for coordinating the various scientific departments in order for Gylden to reach its development and business goals.

He previously worked as an R&D Manager at Sylus Pharmaceuticals; a company focused on foetal-maternal health. Laurens founded PDC Pharma Limited, a biotechnology company that aims to use synthetic insulin messengers in the treatment of Alzheimer’s disease. He has managed numerous projects, the largest being a multi-site, international, clinical trial for a preeclampsia diagnostic.

He holds a BSc in Neuroscience, an MSc in Economics and is enrolled at the European Centre of Pharmaceutical Medicine (Basel, Switzerland) in the Pharma-train Drug Discovery Program.